

## Selective depletion of spinal noradrenaline inhibits post-decapitation convulsions in rats

M. C. Bosland<sup>1</sup>, D. H. G. Versteeg and W. de Jong<sup>2</sup>

Rudolf Magnus Institute for Pharmacology, University of Utrecht, Vondellaan 6, Utrecht (The Netherlands), 23 April 1979

**Summary.** Local administration of 6-hydroxydopamine in the subarachnoidal space of the spinal cord in rats resulted in a selective long-lasting depletion of spinal noradrenaline, but not of dopamine, and prevented the occurrence of post-decapitation convulsions.

Decapitation of rats and mice in the cervical region is followed by clonic flexor-extensor reflexes (called convulsions). Central administration of catecholamine depleting agents strongly suppresses these reflexes<sup>3-5</sup>. This report concerns the effect of selective depletion of spinal noradrenaline on them.

**Methods.** Male albino rats (Wistar, WU, obtained from CPB-TNO, Zeist) weighing 200-240 g were used as experimental animals. The subarachnoidal space of the spinal cord was cannulated under ether anesthesia through a small incision in the atlanto-occipital membrane as described by Yaksh and Rudy<sup>6</sup>. 6-Hydroxydopamine (6-OHDA) was injected over a 30-sec period at the level of T<sub>5</sub>-T<sub>6</sub> at a dose of 250 µg in a volume of 5 µl vehicle (0.9% NaCl solution containing 1 mg/ml ascorbic acid). After injection the cannula was left in position for 1-2 min. Control animals received vehicle only. The rats were decapitated 7, 31 and 42 days after 6-OHDA administration and the presence or absence of clonic convulsions was recorded for each animal; the rats were observed for 2 min. The thoraco-lumbar region of the spinal cord and the brain were quickly removed and the medulla oblongata/pons, cortex cerebri

depressed at 31 days, but not at 7 and 42 days after treatment. DA levels were moderately affected only in the spinal cord at 7 days, but not at 31 and 42 days after 6-OHDA administration.

**Discussion.** Post-decapitation convulsions have been suggested to be a phenomenon resulting from the disappearance of the tonic inhibition of spinal interneurons mediated by bulbospinal NA neurons<sup>5,10,11</sup>. In a recent study Suenaga et al.<sup>10</sup> could not rule out the possibility that cortical or hypothalamic NA was involved in these convulsions, since they administered 6-OHDA intracerebroventricularly and consequently depleted NA not only in the spinal cord but also in these brain regions. In the present report we have shown that selective depletion by 6-OHDA of spinal NA but not DA fully prevented the occurrence of post-decapitation convulsions. Serotonin depletion by centrally administered 5,6-dihydroxytryptamine enhanced these convulsions<sup>12</sup>. There is as yet no evidence for the involvement of other transmitter systems in the post-decapitation convulsions. From the results of the present study we conclude that intact spinal NA transmission is essential for the phenomenon of post-decapitation convulsions.

Noradrenaline and dopamine concentrations in several regions of the central nervous system at various times after spinal administration of 6-hydroxydopamine (6-OHDA)

Time after treatment	Regions	Noradrenaline (µg/g tissue)		Dopamine (µg/g tissue)	
		Control	6-OHDA	Control	6-OHDA
7 days	Cortex cerebri	0.514 ± 0.037 (8)	0.444 ± 0.041 (4)	0.217 ± 0.037 (8)	0.168 ± 0.017 (4)
	Medulla oblongata/pons	0.730 ± 0.054 (8)	0.564 ± 0.048 (4)	0.205 ± 0.030 (8)	0.233 ± 0.025 (4)
	Spinal cord	0.638 ± 0.016 (8)	0.027 ± 0.008 <sup>c</sup> (4)	0.112 ± 0.011 (8)	0.057 ± 0.010 <sup>b</sup> (4)
31 days	Cortex cerebri	0.390 ± 0.036 (9)	0.340 ± 0.042 (10)	0.211 ± 0.035 (9)	0.206 ± 0.024 (10)
	Medulla oblongata/pons	1.220 ± 0.138 (8)	0.850 ± 0.067 <sup>a</sup> (10)	0.380 ± 0.118 (7)	0.430 ± 0.142 (10)
	Spinal cord	0.390 ± 0.067 (9)	0.004 ± 0.003 <sup>c</sup> (10)	0.080 ± 0.014 (9)	0.050 ± 0.019 (10)
	Hypothalamus	2.570 ± 0.229 (9)	2.210 ± 0.321 (10)	0.360 ± 0.047 (9)	0.360 ± 0.048 (10)
42 days	Cortex cerebri	0.502 ± 0.068 (7)	0.546 ± 0.046 (9)	0.236 ± 0.040 (7)	0.303 ± 0.051 (9)
	Medulla oblongata/pons	0.804 ± 0.076 (7)	0.770 ± 0.122 (9)	not measured	not measured
	Spinal cord	0.438 ± 0.042 (7)	0.014 ± 0.004 <sup>c</sup> (9)	0.099 ± 0.006 (7)	0.089 ± 0.009 (9)

Data are expressed as mean ± SEM; the number of animals per group is given in brackets. Catecholamines were assayed using a fluorimetric method (7 and 42 days) or a radiometric method (31 days). <sup>a</sup>p < 0.05; <sup>b</sup>p < 0.01; <sup>c</sup>p < 0.001, for differences between 6-OHDA-treated rats and controls (Student's t-test; 2-tailed).

and, in 1 experiment, the hypothalamus were dissected. Noradrenaline (NA) and dopamine (DA) levels were determined fluorimetrically<sup>7,8</sup>. In 1 experiment a combined radiochemical assay for NA and DA was used as described by van der Gugten et al.<sup>9</sup>. The catecholamine measurements were corrected for recoveries and calculated on the basis of wet tissue weight. Student's t-test was used for statistical evaluation of differences.

**Results.** The decapitation of control animals was always followed within 3-5 sec by clonic convulsions lasting 20-30 sec. The convulsions were completely absent at 7, 31 and 42 days after 6-OHDA pretreatment. The table shows catecholamine levels in various parts of the central nervous system at various times after 6-OHDA administration. NA in the spinal cord fell to a very low level, without statistically significant changes in NA content of cortex and hypothalamus. NA levels in the medulla oblongata were slightly

- 1 Present address: Central Institute for Nutrition and Food Research, Zeist (The Netherlands).
- 2 To whom reprint requests should be directed.
- 3 U.G. Kamath and U.K. Seth, *Neuropharmacology* 10, 571 (1971).
- 4 E. W. Eichbaum and W. J. Yasaka, *Experientia* 29, 816 (1973).
- 5 J. S. Richardson and D. M. Jacobowitz, *Brain Res.* 58, 117 (1973).
- 6 T. L. Yaksh and T. A. Rudy, *Physiol. Behav.* 17, 1031 (1976).
- 7 A. H. Anton and D. F. Sayre, *J. Pharmac. exp. Ther.* 138, 360 (1962).
- 8 R. Laverty and K. M. Taylor, *Analyt. Biochem.* 22, 269 (1968).
- 9 J. van der Gugten, M. Palkovits, H. J. L. M. Wijnen and D. H. G. Versteeg, *Brain Res.* 107, 171 (1976).
- 10 N. Suenaga, K. Yamada and T. Fukuda, *Brain Res.* 122, 165 (1977).
- 11 A. Dahlström and K. Fuxe, *Acta physiol. scand.* 64, suppl. 247, 5 (1965).
- 12 N. R. Myslinski and P. D. Thut, *Life Sci.* 21, 1475 (1977).